Search
Now showing items 1-1 of 1
Cell wall metabolite levels as a function of the growth phase in Staphylococcus aureus and library screening for synergistic combinations of FDA approved drugs against methicillin resistant S. aureus
(2022)
≤ 0.5) like imipenem and biapenem were identified. Moreover, many agents showed weak synergy (0.5 < FICmin ≤ 0.75), such as nafcillin, doripenem, meropenem, and moxalactam....